Kent u de chatbox al? chat met andere beleggers


Bone Therapeutics

Beleggen, aandelen kopen in België, informatie, koersen en analyses

Ivel
Forum verkenner
Forum verkenner
Berichten: 37
Lid geworden op: 20 jul 2020 16:54
waarderingen: 4
Contacteer:

Re: Bone Therapeutics

Bericht door Ivel »

Eigelijk is het een algemene trend bij de kleinere belgische biotech aandelen. De koersen lijken de laatste maanden constant gedrukt te worden bij een good news show.
Is voorlopig lijdzaam toezien en proberen anticiperen bij schommelingen. Geduld zal lonen.





Volg Beursig.com op Twitter en Facebook

     


bertje
Forum elite
Forum elite
Berichten: 6526
Lid geworden op: 30 jul 2012 14:53
waarderingen: 1458
Contacteer:

Re: Bone Therapeutics

Bericht door bertje »

lijkt nieuwe poging te doen om te stijgen.

BONE THERAPEUTICS SA
2,55 +5,80%

Al staan we komende van 22 natuurlijk nog nergens.

Maar bij goed nieuws stijgen we hier gemakkelijk 20 - 30% en dan is het beter te vertrekken van 2.55 dan 2.20 ;)

bertje
Forum elite
Forum elite
Berichten: 6526
Lid geworden op: 30 jul 2012 14:53
waarderingen: 1458
Contacteer:

Re: Bone Therapeutics

Bericht door bertje »

halted

Door 2 orders
1 4.700 2,63

1 988 2,62

2.76 zichtbaar in boekje, misschien aanval op de 2.7 vandaag en dan volgende dagen nieuws?

Ivel
Forum verkenner
Forum verkenner
Berichten: 37
Lid geworden op: 20 jul 2020 16:54
waarderingen: 4
Contacteer:

Re: Bone Therapeutics

Bericht door Ivel »

Ik verwacht deze week een positieve opsteker met de halfjaar resultaten, zeker gezien het nieuws van vorige week. Mooi om te zien dat men niet stil zit :)

bertje
Forum elite
Forum elite
Berichten: 6526
Lid geworden op: 30 jul 2012 14:53
waarderingen: 1458
Contacteer:

Re: Bone Therapeutics

Bericht door bertje »

verbaasd me dat we terug zo worden afgestraft.
2,5 +3,73%

Toen we 2.63 stonden en ik het lege boekje zag (enkel 6000 a 2.76 was zwaar) dacht ik dat we fors gingen doorstijgen.

Heb er bijgekocht , maar door pakketten boven de 3.5 ligt gem. toch nog stuk hoger.

dandev
Forum verkenner
Forum verkenner
Berichten: 32
Lid geworden op: 07 jan 2016 22:10
waarderingen: 8
Contacteer:

Re: Bone Therapeutics

Bericht door dandev »

Bone Therapeutics reports half year 2020 results


Recruitment of JTA-004 phase III study in knee osteoarthritis on track to be completed by year-end

Phase IIb trial with ALLOB in tibial fractures approved in most countries ready to start in H2 2020

A total amount of EUR 15.0 million committed gross proceeds raised in two successful funding operations to support clinical progress

Broadening product portfolio from orthopedics into inflammatory conditions, leveraging Bone Therapeutics’ allogeneic MSC platform




Management to host conference call today at 6:00 pm CEST today - details provided below


Gosselies, Belgium, 26 August 2020, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company established to address unmet medical needs in orthopedics and other diseases, today provides a business update and its financial results for the six-month period ended 30 June 2020, prepared in accordance with IFRS as adopted by the European Union, and the outlook for the remainder of the year.

Miguel Forte, MD, PhD, Chief Executive Officer of Bone Therapeutics, commented: “Bone Therapeutics is continuing to make significant progress with the development of our clinical assets closer to patients. The pivotal JTA-004 phase III clinical trial in knee osteoarthritis is now recruiting in all countries and the phase IIb study with ALLOB in tibial fractures has received regulatory clearance in nearly all countries applied. The successful fundraises in previous months further strengthen our cash position allowing us to execute our business strategy to progress both lead candidates through their late-stage clinical development. Furthermore, the recent funding from the Walloon Region supporting the expansion of our pipeline into inflammatory conditions further underscores the potential of our MSC platform to drive much needed innovation in a wide range of therapeutic areas. This recent progress and the appointment of Stefanos Theoharis as Chief Business Officer will further accelerate strategic discussions regarding the commercialization of both our clinical assets with potential business partners. With the anticipated completion of patient recruitment of JTA-004 phase III trial, the start of the ALLOB phase IIb study and the 24 months readout of the phase IIa trial with ALLOB in spinal fusion, Bone Therapeutics is progressing towards an exciting second half of the year.”


Operational and Corporate Highlights
• During the first wave of the global COVID-19 pandemic, Bone Therapeutics decided to reduce the recruitment activities of its studies to a minimum to support healthcare systems in the respective trial countries enabling them to concentrate on treating COVID-19 patients whilst necessary.
• Following the lifting of the COVID-19 lockdown measures, Bone Therapeutics initiated the recruitment of its pivotal phase III study with the next generation of viscosupplement, JTA-004, targeting osteoarthritic knee pain in mid-May 2020. The clinical trial has now been approved in all seven territories in which Clinical Trial Applications (CTA) of the study had been submitted, these being Belgium, Czech Republic, Denmark, Hong Kong, Moldavia, Poland and United Kingdom. Approximately 20% of the targeted assessable patients have been treated since the initiation of the trial.
• The phase IIb study of its allogeneic cell therapy product, ALLOB, in patients with difficult tibial fractures has received approval from regulatory authorities in the main six of the seven European countries in which the Company has applied for the study. Patient recruitment is expected to start in the second half of the year.
• In March, the company appointed Stefanos Theoharis, PhD as Chief Business Officer (CBO), further strengthening its management team. With more than 15 years of business development experience in the pharma and biotech industry, specifically in the cell and gene therapy space, Stefanos will be responsible for the company’s corporate development activities and the execution of its business strategy.
• Post period, in August, Bone Therapeutics was granted EUR 1.0 million in non-dilutive funding under the form of recoverable cash advances from the Walloon Region, Belgium. This funding will provide additional financial support to advance its current phase III clinical study with JTA-004.
• Also in August, the Company received two additional grants with a total value of EUR 0.6 million from the Walloon Region for research and initial preparatory steps towards clinical development of BT-20, its new allogeneic and off-the-shelf cell therapy product, leveraging its expertise in Mesenchymal Stromal Cell (MSC) biology to expand its portfolio from orthopedics and bone diseases to inflammatory conditions. Both grants, as well as the recoverable cash advances, are subject to conditions precedent.

Financial Highlights for the period ended 30 June 2020
• In April, Bone Therapeutics announced that it secured EUR 11.00 million financing. The financing operation consisted of EUR 4.75 million bridge loans, EUR 1.26 million in equity private placement (through immediate conversion of convertible bonds (CBs)) by existing shareholders and, on an as-needed basis, a EUR 4.99 million in private placement of CBs.
• Subsequently, in May, Bone Therapeutics received an additional EUR 4.00 million of financing from existing investors in the form of subordinated bonds with the option to convert. The total amount of committed gross proceeds for both funding operations amount to EUR 15.00 million.
• The structure of the financing (mainly non-dilutive) combined with an operating loss for the period led to a negative shareholders’ equity of EUR 4.6 million at the end of June 2020.
• During the first six months of 2020, total operating income amounted to EUR 1.04 million, a slight decrease compared to the same period in 2019 (EUR 1.68 million).
• Operating loss for the period amounted to EUR 9.10 million, compared to EUR 5.44 million in H1 2019.
• The Company ended the first six months of 2020 with EUR 10.04 million in cash and cash equivalents. Cash used for the period amounted to EUR 8.86 million, excluding net proceeds obtained from financing activities, compared to EUR 5.12 million over the same period of 2019.

Outlook for the remainder of 2020
• At the current recruitment rate, patient enrolment for the JTA-004 phase III study is on track to be completed before year-end. Bone Therapeutics anticipates reporting topline results on the 3-month primary endpoint and 6-month follow-up period in the second half of 2021.
• The Company expects to initiate clinical trial activities and patient recruitments for the ALLOB phase IIb study in patients with difficult tibial fractures in European clinical centers in the second half of 2020.
• As the evolution of the pandemic is uncertain and cannot be predicted at present, both studies may encounter a delay compared to the anticipated schedule. The situation in Europe and Hong Kong is actively and closely monitored on an ongoing basis.
• In November, Bone Therapeutics plans to initiate the first discussions with the US FDA (Food and Drug Administration) in preparation for the next steps in the clinical development of JTA-004 in the US, a large, important market.
• In the second half of 2020, the Company also expects to report results from the 2-year follow-up period of the phase IIa study with ALLOB in patients undergoing a spinal fusion procedure.
• Bone Therapeutics continues to hold discussions with potential partners to explore business opportunities. It also intends to prepare a fundraise in the second half of 2020. Existing shareholders have already taken a pre-commitment to participate.
• Good cost and cash management will remain a key priority, as already reflected in our operating expenses. Cash used for the full year 2020 is anticipated to amount to EUR 15.00-16.00 million, largely driven by external costs associated with increased clinical trial activities and costs associated with the JTA phase III and ALLOB phase IIb clinical studies. Taking into account the total committed gross proceeds of EUR 15 million raised through the Private Placements and in bridge loans in April and May of this year, the convertible bonds and the recoverable cash advances granted by the Walloon Region, the Company anticipates having sufficient cash to carry out its business objectives into Q2 2021. This assumes normal operation, as there may be further effects of the ongoing COVID-19 epidemic. Potential delay in patient recruitment in both studies could lower the expected cash burn and extend the anticipated cash runway further into 2021.

Conference call
Miguel Forte, MD, PhD, Chief Executive Officer, and Jean-Luc Vandebroek, Chief Financial Officer, will host a conference call today at 6:00 pm CEST. To participate in the conference call, please select your phone number below and use the conference ID 927 9360 0923#.

Belgium: +32 2 290 9360
France: +33 1 7095 0103
United Kingdom: +44 208 080 6592
United States: +1 646 876 9923

The presentation will be made available on the Investors section - Presentations of the Bone Therapeutics website shortly prior the call.

bertje
Forum elite
Forum elite
Berichten: 6526
Lid geworden op: 30 jul 2012 14:53
waarderingen: 1458
Contacteer:

Re: Bone Therapeutics

Bericht door bertje »

Geen groot nieuws, maar toch heel wat lichtpuntjes.

The successful fundraises in previous months further strengthen our cash position allowing us to execute our business strategy to progress both lead candidates through their late-stage clinical development. Furthermore, the recent funding from the Walloon Region supporting the expansion of our pipeline into inflammatory conditions further underscores the potential of our MSC platform to drive much needed innovation in a wide range of therapeutic areas. This recent progress and the appointment of Stefanos Theoharis as Chief Business Officer will further accelerate strategic discussions regarding the commercialization of both our clinical assets with potential business partners. With the anticipated completion of patient recruitment of JTA-004 phase III trial, the start of the ALLOB phase IIb study and the 24 months readout of the phase IIa trial with ALLOB in spinal fusion, Bone Therapeutics is progressing towards an exciting second half of the year.”

Post period, in August, Bone Therapeutics was granted EUR 1.0 million in non-dilutive funding under the form of recoverable cash advances from the Walloon Region, Belgium. This funding will provide additional financial support to advance its current phase III clinical study with JTA-004.
Also in August, the Company received two additional grants with a total value of EUR 0.6 million from the Walloon Region for research and initial preparatory steps towards clinical development of BT-20, its new allogeneic and off-the-shelf cell therapy product, leveraging its expertise in Mesenchymal Stromal Cell (MSC) biology to expand its portfolio from orthopedics and bone diseases to inflammatory conditions. Both grants, as well as the recoverable cash advances, are subject to conditions precedent.

In April, Bone Therapeutics announced that it secured EUR 11.00 million financing. The financing operation consisted of EUR 4.75 million bridge loans, EUR 1.26 million in equity private placement (through immediate conversion of convertible bonds (CBs)) by existing shareholders and, on an as-needed basis, a EUR 4.99 million in private placement of CBs.
Subsequently, in May, Bone Therapeutics received an additional EUR 4.00 million of financing from existing investors in the form of subordinated bonds with the option to convert. The total amount of committed gross proceeds for both funding operations amount to EUR 15.00 million.

The Company expects to initiate clinical trial activities and patient recruitments for the ALLOB phase IIb study in patients with difficult tibial fractures in European clinical centers in the second half of 2020.

In November, Bone Therapeutics plans to initiate the first discussions with the US FDA (Food and Drug Administration) in preparation for the next steps in the clinical development of JTA-004 in the US, a large, important market.
In the second half of 2020, the Company also expects to report results from the 2-year follow-up period of the phase IIa study with ALLOB in patients undergoing a spinal fusion procedure.

The Company anticipates having sufficient cash to carry out its business objectives into Q2 2021.

Ivel
Forum verkenner
Forum verkenner
Berichten: 37
Lid geworden op: 20 jul 2020 16:54
waarderingen: 4
Contacteer:

Re: Bone Therapeutics

Bericht door Ivel »

Ben gematigd positief, had geen toename van cashburn verwacht in de eerste helft 2020.
Klinische fases zitten redelijk goed op schema, uitbreiding pipeline (hoop stiekem op meer details van analisten).

bertje
Forum elite
Forum elite
Berichten: 6526
Lid geworden op: 30 jul 2012 14:53
waarderingen: 1458
Contacteer:

Re: Bone Therapeutics

Bericht door bertje »

snap het ook niet.

toen ik de cijfers van bone en mdx zag dacht ik bone zal stijgen en mdx zal een zware pandoering krijgen, wij dalen echter 8% en mdx stijgt???

bij mdx: H1 SELECTMDX® BILLABLE TEST VOLUME DECLINED 48% TO 6,485 VERSUS 12,528 LAST YEAR, is het misschien omdat ze geld verliezen per test dat men een zo laag mogelijk aantal wil??

Ivel
Forum verkenner
Forum verkenner
Berichten: 37
Lid geworden op: 20 jul 2020 16:54
waarderingen: 4
Contacteer:

Re: Bone Therapeutics

Bericht door Ivel »

Ik zag de cijfers, verbazend koersverloop dat ik ook niet geheel begrijp :?:

Deelnemen aan het forum + meer functies?

Discussieer met duizenden beleggers, minder
advertenties, ideaal voor smartphone, betere
gebruikservaring en gratis abonneren op favoriete
onderwerpen. Registreer binnen 1 minuut!


Plaats reactie